Q-omics provides the consensus-scored PTCHD4 profile across patient tissues and cancer cell-line models. PTCHD4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PTCHD4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PTCHD4 RNA expression shows 16,004 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, THCA, and UVM as cancer lineages where PTCHD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCHD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCHD4 survival associations across molecular data types. PTCHD4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCHD4 RNA expression–survival associations across cancer types. High PTCHD4 expression shows unfavorable associations in STAD and BLCA, but favorable associations in KIRP, KIRC, LIHC and SCLC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PTCHD4 RNA expression.
This table summarizes PTCHD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTCHD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCHD4 shows lower tumor expression in LUSC and BRCA and higher tumor expression in THCA, KIRP, HNSC and LIHC. The THCA box plot shows higher PTCHD4 RNA expression in tumor versus normal tissue (log2 FC = +2.601, t-test p < 0.001).
This table shows molecular features associated with PTCHD4 in patient tissues and cancer cell lines. In patient samples, PTCHD4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTCHD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
